Skip to main content
main-content

Kidney cancer

Kidney cancer

17-05-2019 | Oncology | News | Article

USA approves first-line avelumab–axitinib for advanced RCC

Click through to read more

29-04-2019 | Oncology | News | Article

FDA approves first-line pembrolizumab–axitinib for advanced RCC

Click through to read more

05-03-2019 | Kidney cancer | News | Article

Cabozantinib efficacy extends to non-clear-cell RCC

Almost three-quarters of patients with non-clear-cell renal cell carcinoma may benefit from treatment with the tyrosine kinase receptor inhibitor cabozantinib, suggesting its efficacy is not limited to clear-cell disease, say researchers.

21-02-2019 | Kidney cancer | News | Article

Immunotherapy-based regimens show promise in non-clear-cell RCC

Three trials point to the potential of regimens incorporating agents targeting the programmed cell death protein 1 or its ligand in patients with non-clear-cell renal cell carcinoma.

20-02-2019 | Kidney cancer | News | Article

Tivozanib improves refractory advanced RCC outcomes

The phase III TIVO-3 trial has found that both progression-free survival and response are significantly better with tivozanib than sorafenib in patients with refractory metastatic renal cell carcinoma.

19-02-2019 | Kidney cancer | News | Article

Pembrolizumab–axitinib boosts untreated advanced RCC survival

Overall survival is significantly improved with the first-line combination of pembrolizumab and axitinib relative to sunitinib in patients with advanced renal cell carcinoma, shows the KEYNOTE-426 trial.

01-02-2019 | Colorectal cancer | News | Article

EMA gives biosimilar bevacizumab positive opinion

Read more on this decision here

24-01-2019 | Kidney cancer | News | Article

HRQoL greater with nivolumab plus ipilimumab than sunitinib in advanced RCC

Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.

21-01-2019 | Kidney cancer | News | Article

Sustained benefit of VEGFR–TKIs after doublet immunotherapy in metastatic RCC

Second-line treatment with vascular endothelial growth factor receptor–tyrosine kinase inhibitors after failure of nivolumab plus ipilimumab continues to benefit patients with metastatic renal cell carcinoma, report researchers.

18-01-2019 | Kidney cancer | News | Article

Potential ‘risk of harm’ for older women with adjuvant sunitinib for RCC

Adjuvant treatment with sunitinib may be associated with an increased mortality risk for older female patients with renal cell carcinoma, suggests a post-hoc analysis of the ASSURE trial that compared sunitinib and sorafenib with placebo.

11-01-2019 | Oncology | News | Article

Concomitant TKI–PPI use may adversely affect cancer patient survival

Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.

15-11-2018 | Oncology | News | Article

Genomic annotation improves MSKCC risk model for renal carcinoma

Adding the mutation status of three genes linked to renal cell carcinoma improves the prognostic value of the Memorial Sloan Kettering Cancer Center risk model for patients receiving tyrosine kinase inhibitors for metastatic disease, research shows.

26-10-2018 | Oncology | News | Article

First-line avelumab–axitinib outperforms sunitinib in advanced RCC

Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.

13-07-2018 | Kidney cancer | News | Article

Germline mutations detected in advanced RCC patients

Germline mutations may be common in patients with advanced renal cell carcinoma and may have the potential to guide therapy if detected, US researchers report.

19-06-2018 | Oncology | Main feed | News

IMmotion151 PROs add support for first-line atezolizumab plus bevacizumab in mRCC

Patient-reported outcomes from the IMmotion151 study favor atezolizumab plus bevacizumab as a first-line regimen for the treatment of patients with metastatic clear cell renal cell carcinoma.

19-06-2018 | Kidney cancer | News | Article

Need for nephrectomy challenged in some sunitinib-treated metastatic renal cancers

Results of the phase III CARMENA trial show that treatment with sunitinib alone is as good as treatment with nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic renal cell carcinoma.

22-05-2018 | Non-small-cell lung cancer | Main feed | News

Atezolizumab receives NICE recommendation for NSCLC

Read more on this UK decision here

26-04-2018 | Kidney cancer | News | Article

FDA backs nivolumab plus ipilimumab for first-line advanced RCC

Click for the details of this announcement

23-03-2018 | Kidney cancer | News | Article

Promising early data reported for avelumab plus axitinib in advanced RCC

Results from the JAVELIN Renal 100 study suggest that avelumab plus axitinib is a tolerable combination, with encouraging antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

20-02-2018 | Kidney cancer | News | Article

Phase Ib trial shows promising treatment combination for advanced RCC

Axitinib plus pembrolizumab can be tolerated and shows promising antitumor activity in patients with advanced renal cell carcinoma, researchers from an early-stage US trial say.

image credits